The Centers for Medicare and Medicaid Services plans to terminate four demonstration projects by the end of 2025, closing out ...
It's marketed as a generic option to name-brand mood meds, but it's been recalled for the same reason a competitor was just ...
The acquired portfolio consists of 13 ANDAs already approved by the Food and Drug Administration and one pending approval.
A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...